Body mass index, obesity, and psychopathology in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 40-46

  Subramaniam, Mythily ^a   Lam, Max ^a   Guo, Meng En ^a   He, Vincent Y F ^a   Lee, Jimmy ^a,b   Verma, Swapna ^a   Chong, Siow Ann ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antipsychotics; Body mass index; Chinese; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHINESE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; SUSPICIOUSNESS; UNDERWEIGHT;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; SINGAPORE; WEIGHT LOSS;

EID: 84891743690     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000058     Document Type: Article

References (45)

1. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry. 2001;46(6):549-555.
2. Limosin F, Gasquet I, Leguay D, et al. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand. 2008;118(1):19-25.
3. Fountoulakis KN, Siamouli M, Panagiotidis P, et al. Obesity and smoking in patients with schizophrenia and normal controls: a case-control study. Psychiatry Res. 2010;176(1):13-16.
4. Hsiao CC, Ree SC, Chiang YL, et al. Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan. Psychiatry Clin Neurosci. 2004;58(4):403-409.
5. Kitabayashi Y, Narumoto J, Kitabayashi M, et al. Body mass index among Japanese inpatients with schizophrenia. Int J Psychiatry Med. 2006;36(1):93-102.
6. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65(suppl 18):13-26.
7. Arango C, Bobes J, Aranda P, et al. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res. 2008;104(1-3):1-12.
8. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights [review]. J Clin Psychiatry. 2007;68(suppl 12):18-26.
9. McCreadie RG, , Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534-539.
10. Vancampfort D, Probst M, Sweers K, et al. Relationship between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatr Scand. 2011;123(6):423-430.
11. Vancampfort D, Probst M, Knapen, J, et al. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res. 2012;126(1):12-20.
12. llison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215-220.
13. Salokangas RK, Honkonen T, Stenga?rd E, et al. Body mass index and functioning in long-term schizophrenia. Results of the DSP project. Eur Psychiatry. 2007;22(5):313-318.
14. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease [review]. Am Heart J. 2005;150(6):1115-1121.
15. Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116(5):317-333.
16. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54(4):565-567.
17. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-57.
18. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62(4):231-238.
19. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res. 2003;59(1):19-27.
20. National Health Survey 2010. Epidemiology and Disease Control Division, Ministry of Health, Singapore. Pages 22-30. Available at: http://www.moh.gov.sg/ content/dam/moh-web/Publications/Reports/2011/NHS2010%20-%20low%20res.pdf. Accessed May 21, 2012.
21. Chong SA, Campbell A, Chee M, et al. The Singapore flagship programme in translational and clinical research in psychosis. Early Interv Psychiatry. 2011;5(4):290-300.
22. Sim K, Lee J, Subramaniam M, et al. Integrated genetic and genomic approach in the Singapore Translational and Clinical Research in Psychosis Study: an overview. Early Interv Psychiatry. 2011;5(2):91-99.
23. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2007.
24. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667.
25. Barnes TRE, Paton C. Improving prescribing practice in psychiatry: the experience of the Prescribing Observatory for Mental Health (POMH-UK). Int Rev Psychiatry (Abingdon, England). 2011;23(4):328-335.
26. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
27. World Health Organization. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva, Switzerland: World Health Organization; 1995.
28. Gurpegui M, Mart?nez-Ortega JM, Gutierrez-Rojas L, et al. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):169-175.
29. Bays HE, Chapman RH, Grandy S, the SHIELD Investigators' Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61(5):737-747.
30. National Center for Health Statistics. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD; 2012. Available at: http://www.cdc.gov/nchs/data/hus/hus11.pdf#listfigures. Accessed on November 3, 2012.
31. Vancampfort D, Knapen J, Probst M, et al. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012;125(5):352-362.
32. Xiang YT, Wang CY, Si TM, et al. Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients: findings of the Research on Asia Psychotropic Prescription (REAP) studies. Aust N Z J Psychiatry. 2011;45(3):193-198.
33. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Euro J Clin Pharmacol. 1999;55:177-184.
34. Aichhorn W, Gasser M, Weiss EM, et al. Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. Curr Neuropsychol. 2005;3(1):73-85.
35. Zhang XY, Tan YL, Zhou DF, et al. Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res. 2007;41:997-1004.
36. Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry. 2006;163:1276-1279.
37. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22:244-251.
38. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry. 2001;62:231-238.
39. Yang Y, Li W, Zhao J, et al. Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients. Behav Brain Funct. 2012;8:11.
40. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry. 2008;13(10):918-929.
41. Vancampfort D, Probst M, Scheewe T, et al. The functional exercise capacity is correlated with global functioning in patients with schizophrenia. Acta Psychiatr Scand. 2012;125(5):382-387.
42. Li Q, Zhang J, Zhou YN, et al. Obesity and gastric cancer. Front Biosci. 2012;17:2383-2390.
43. LahtiM, Tiihonen J,Wildgust H, et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia [published online ahead of print]. Psychol Med. 2012;42(11):2275-2285.
44. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83-88.
45. Vancampfort D, Probst M, Skjaerven L, et al. Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia. Phys Ther. 2012;92(1):11-23.